Testing ZG005 with Gecacitinib in advanced cervical cancer
Tests ZG005 with Gecacitinib, with or without bevacizumab, in adults with advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with advanced cervical cancer. It tests ZG005 with Gecacitinib, with or without bevacizumab, for safety and early effect.
- Age
- 18 to 75 years
- Sex
- Women only
- Disease stage
- Advanced cervical cancer confirmed by tissue or cell tests: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
Main reasons for not taking part
- Anyone the investigator judges unsuitable for the study for any reason
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07080216, who can take part
Where in China
- Zhejiang Cancer HospitalHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Trial code
- NCT07080216
- Record updated
- 5 January 2026
- Original description
This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.Read full original descriptionShow less
A Multicenter, Open-label, Dose-finding and Dose-expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
Inclusion: Fully understand the study and voluntarily sign the informed consent form; Female 18-75 years of age; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; Histologically or cytologically confirmed advanced cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
Exclusion: Patients were deemed unsuitable for participating in the study by the investigator for any reasons.